Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB068 SAD Study in Healthy Subjects
NCT02829541Phase 1Completed
- Sponsor
- Biogen
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB068 in systemic lupus erythematosus (SLE) (6 cohorts), sponsored by Biogen. Primary endpoints: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of participants with clinically significant laboratory assessment abnormalities and 3 more. Started Aug 2016; status: completed.
02
Drugs
BIIB068
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02829541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829541.